Valuation of the use of biomarkers predictive of drug efficacy to enrich responders in oncology drug clinical development
Sloan School of Management.
A. Gregory Sorensen and Teodro Forcht Dagi.
MetadataShow full item record
I study several aspects of the value in performing oncology clinical trials using screening biomarkers to preferentially select and enroll responders. From trial reports and investigational reports on potential biomarkers, I construct a series of six cases comparing the trial as conducted to a hypothetical trial using different screening and eligibility criteria. These cases illustrate, within limits of the model, what difference the use of a plausible biomarker test may have on trial size, cost, number of patients screened, and number of patients exposed to experimental treatment without benefit.
Thesis (S.M.)--Harvard-MIT Division of Health Sciences and Technology; and, (S.M.)--Massachusetts Institute of Technology, Sloan School of Management, 2006.Includes bibliographical references (leaves 57-59).
DepartmentHarvard University--MIT Division of Health Sciences and Technology.; Sloan School of Management.
Massachusetts Institute of Technology
Harvard University--MIT Division of Health Sciences and Technology., Sloan School of Management.